What Triplet Therapeutics does

Triplet Therapeutics is a clinical-stage biotechnology company founded in 2019 and headquartered in Cambridge, Massachusetts. The company is developing therapies that target repeat expansion disorders — the class of genetic diseases caused by expanded trinucleotide repeats in DNA — at their genetic source rather than at the downstream symptomatic level. Its therapeutic platform is oriented toward neurodegenerative and neurological conditions associated with CAG repeat expansions, a category that includes Huntington's disease and several related rare neurological indications.

The company is led by founder Nessan Bermingham (currently Executive Chairman, formerly CEO) and Chief Scientific Officer Alan J. Buckler. With 11–50 employees, Triplet operates as a focused, science-driven private organization. Its business model is the conventional biotech model: advance proprietary therapeutic candidates through preclinical and clinical development, with the long-term value realization pathway being outlicensing, strategic partnership, or potential acquisition by a larger pharmaceutical company.

Triplet has raised an aggregate of $59 million in equity capital within its first year of operation, including a $10 million seed/Series A led by Atlas Venture in January 2019 and a $49 million Series B in December 2019 co-led by MPM Capital and Pfizer Venture Investments, with additional participation from Alexandria Venture Investments, Atlas Venture, Invus, and Partners Innovation Fund. The presence of a major pharmaceutical venture investor alongside top-tier life-sciences specialists provides both capital and implicit industry validation of the platform's scientific and commercial premise.

Name

Triplet Therapeutics

Legal name

triplettx.com

Website

https://triplettx.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Triplet Therapeutics is a Cambridge, MA-based clinical-stage biotechnology company founded in 2019 that develops therapies targeting repeat expansion disorders at their genetic source, with $59M raised from Pfizer Ventures and other top-tier life-science investors.

Ownership category

akta.pro rank

Product category

Genetic Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Nucleic acid therapeutics
• Repeat expansion disorders
• Genetic disease treatments
• Huntington's disease therapy
• DNA repeat therapies

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Others

Revenue model

1. Sports betting commission: Revenue generated from sports betting margins. The platform takes a commission through odds pricing (margins vary by tournament and event importance).
2. Casino games and slots: Revenue from online casino games including slots from providers like Play'n GO, Pragmatic Play, and NetEnt. Includes house edge on games.
3. Live casino: Revenue from live dealer casino games with real-time streaming.
4. Crypto transactions: Processing fees and spreads on cryptocurrency deposits and withdrawals using BybitPay and direct crypto transfers.
5. Bonus wagering requirements: Revenue generated from bonus funds that are not successfully wagered according to terms (60x for casino, 5x for sports).

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Triplet Therapeutics is a clinical-stage biotechnology company developing nucleic acid-based therapeutics that treat repeat expansion disorders at their genetic source. The company focuses on conditions caused by expanded DNA repeat sequences, with the goal of suppressing toxic gene products underlying diseases such as Huntington's disease. Triplet is building a pipeline of disease-modifying therapies targeting the root genetic cause of repeat expansion disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Repeat expansion disorder therapies

Quantifiable outcome

• Express boost up to 1.2x on accumulators with 4+ events
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Sports Ambassadors (Football and Cricket)coreGTM or Marketing PartnerMostbet partners with sports ambassadors from football and cricket to promote the brand internationally. These partnerships help expand brand presence in key markets through athlete endorsements.
• Local Kazakhstani Sports FiguresminorGTM or Marketing PartnerRegional brand promotion through partnerships with local sports personalities in Kazakhstan for targeted marketing campaigns.
• Game Providers (Play'n GO, Pragmatic Play, NetEnt, 3 Oaks Gaming)coreTechnology or IntegrationIntegration with major casino game providers including Play'n GO, Pragmatic Play, NetEnt, and 3 Oaks Gaming for slot content. Games include titles like Book of Dead, Gates of Olympus, Gonzo's Quest, and 3 Coins: Egypt.
• BybitPaycoreTechnology or IntegrationCryptocurrency payment processing through BybitPay enabling deposits starting from 1000 KZT equivalent in crypto.
• Kaspi BankcoreTechnology or IntegrationPayment integration with Kaspi Bank for Kazakhstani users, enabling deposits from 1000 KZT via bank transfer and Kaspi Pay.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company developing allele-selective and silencing ASOs for Huntington's disease, myotonic dystrophy type 1, and other repeat expansion disorders—directly competing with Triplet's stated mechanism and indication focus.
• uniQure: Gene therapy company advancing AMT-130, an AAV-based therapy for Huntington's disease, representing a competing disease-modifying approach to repeat expansion disorders and a direct indication overlap with Triplet's lead programs.
• Regulus Therapeutics: MicroRNA-targeted therapeutics company developing RGLS8426 for repeat expansion disorders including ADPKD and CNS indications, with a comparable nucleic-acid / oligonucleotide-based mechanism targeting rare genetic diseases.

Broad incumbents

• Ionis Pharmaceuticals: Established antisense oligonucleotide platform company that co-developed tominersen with Roche for Huntington's disease; its broader ASO pipeline and platform licensing model position it as both a competitor and a potential partner relative to Triplet's nucleic-acid approach.
• Alnylam Pharmaceuticals: RNAi therapeutics leader with a broad nucleic-acid platform that has validated rare genetic disease development, manufacturing, and commercialization at scale—relevant comparator for Triplet's modality and target indication profile.
• Sage Therapeutics: CNS-focused biopharma commercializing rare neurological disease therapies; relevant comparator for CNS orphan drug development, regulatory navigation, and partnership dynamics in Triplet's disease space.
• Denali Therapeutics: Clinical-stage biopharma developing therapeutics for neurodegenerative diseases with a focus on genetic and rare CNS indications; broadly comparable as a larger, well-capitalized player in Triplet's disease space.

Emerging players

• Solid Biosciences: Genetic medicine company developing AAV gene therapies for rare neuromuscular and CNS indications; comparable as a small-cap rare disease gene therapy platform at similar stage of clinical translation.
• Passage Bio: Clinical-stage AAV gene therapy company focused on rare monogenic CNS diseases, including programs overlapping with repeat expansion and other neurodegenerative indications relevant to Triplet's pipeline.
• Lexeo Therapeutics: Clinical-stage gene therapy company targeting CNS and rare genetic diseases, including neurodegenerative indications, with a comparable platform modality and similar stage of development to Triplet.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/tripletthera

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triplet Therapeutics